Sunitinib in Gastroeneteropancreatic Neuroendocrine Tumor (GEP-NET) after Failure of Previous Treatments, Including Everolimus: A Series of Five Clinical Cases

#892

Introduction: In a recent phase III study, Sunitinib has shown significant improvement of progression-free survival in patients with pancreatic NET.

Aim(s): We evaluate metastatic G1-G2 GEP NET treated with Sunitinib after failure of almost three previous treatments, including Everolimus, to assess efficacy, safety and tolerability also in late line of treatment, and to evaluate if Sunitinib maintained its efficacy also after progression to Everolimus.

Materials and methods: From February 2011 to December 2013, five GEP NET pts with progressive disease were treated with Sunitinib 37.5 mg orally daily after almost three lines of treatment (somatostatine analog, Everolimus, chemotherapy, PRRT); two pts received Sunitinib in IV line, one pt in V line, two pts in VI line. The primary tumor site was pancreas in two pts, gastrointestinal tract in three pts. Patients were followed for evidence of toxicity, response assessed using RECIST criteria, and survival.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Marconcini R, Galli L, Antonuzzo A, Bracco E, Farnesi A,

Keywords: sunitinib, everolimus,